Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

View Full Paper
Ask AI
Bookmark
Share

Authors

XBXiaojing BaoJHJian Huang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows distinct clinical features and outcomes in AYA patients with myeloproliferative neoplasms, indicating the need for targeted therapies.

Key Points

  • Evaluate the long-term outcomes and genomic differences between AYA and non-AYA patients with essential thrombocythemia and polycythemia vera.
  • Retrospective analysis of data from 33 Chinese medical centers
  • Comparison of clinical features and outcomes between AYA and non-AYA patients
  • Utilization of next-generation sequencing for mutational analysis
  • AYA patients with essential thrombocythemia exhibited a higher overall survival rate and better outcomes compared to non-AYA patients
  • Genomic profiles revealed distinct non-driver mutations prevalent in AYA patients
  • No significant survival differences noted between AYA and non-AYA patients with polycythemia vera

Cite This Study

Bao et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e074https://doi.org/10.1182/blood-2025-7352
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults2026
  2. 2Clinical features, management, and outcomes of adolescents and young adults with myeloproliferative neoplasms.2026
  3. 3Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.2025
  4. 4Myeloproliferative neoplasms in the young: unique disease patterns and therapeutic strategies2026
  5. 5From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study2026 · 1 citations